Scrip is part of Pharma Intelligence UK Limited

This site is operated by Pharma Intelligence UK Limited, a company registered in England and Wales with company number 13787459 whose registered office is 5 Howick Place, London SW1P 1WG. The Pharma Intelligence group is owned by Caerus Topco S.à r.l. and all copyright resides with the group.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction

Viking Therapeutics, Inc.

http://www.vikingtherapeutics.com/

Latest From Viking Therapeutics, Inc.

AASLD Notebook: Inventiva Eyes Second-To-Market Possibility In NASH

Inventiva’s pan-PPAR agonist and Terns’ combination strategy are targeting the NASH treatment paradigm after expected approval of Madrigal’s resmetirom. Viking is hoping to prove a better THRβ drug profile than Madrigal.

Business Strategies Clinical Trials

Terns Hits In NASH, But Trails Its Rivals

TERN-501 monotherapy looks serviceable in a mid-stage NASH trial, but others are ahead. Perhaps partnership is the way forward.

Clinical Trials Companies

Intercept Ends NASH Development, But Other Firms’ FXR Agonist Programs Ongoing

While Intercept is calling it quits in NASH with its FXR agonist obeticholic acid following a second complete response letter, other companies are staying the course with Phase II molecules in the class.

Drug Approval Standards Complete Response Letters

Merck And Altimmune Vie To Be Leaders In NAFLD And NASH

While progress in NASH has been slow for years, two dual GLP-1/GR agonists from rivals Merck & Co and Altimmune are showing mid-stage promise.

Metabolic Disorders Commercial
See All

Company Information

  • Industry
  • Biotechnology
  • Pharmaceuticals
UsernamePublicRestriction

Register